Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results Read more about Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results
Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019 Read more about Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting Read more about Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September Read more about Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September
Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019 Read more about Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer Read more about Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) Read more about Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)